In addition, patients with relapsed or refractory AML who received the combination of chidamide, decitabine, cytarabine, atramycin, and granulocyte colony-stimulating factor had an overall response rate of 46.2%, with 24 achieving complete remission and 19 reaching complete remission with incomplete blood count recovery (Table 3).102. This evidence concerns the gene CSF3 and acute myeloid leukemia.